Alterations in cellular iron metabolism provide more therapeutic opportunities for cancer

International Journal of Molecular Sciences

Volumn 19, Issue 5, 2018, Pages

  Zhou, Liangfu ^a   Zhao, Bin ^a   Zhang, Lixiu ^a   Wang, Shenghang ^a   Dong, Dandan ^a   Lv, Huanhuan ^a   Shang, Peng ^a  

^a NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

Author keywords

Cancer; Iron chelators; Iron metabolism; Redox homeostasis; Targeted therapy

Indexed keywords

FRATAXIN; IRON REGULATORY FACTOR; MICRORNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSFERRIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ANTIOXIDANT; IRON;

5' UNTRANSLATED REGION; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; IRON METABOLISM; MITOCHONDRIAL RESPIRATION; NEOPLASM; PANCREAS CANCER; REVIEW; ANIMAL; HOMEOSTASIS; METABOLISM; OXIDATION REDUCTION REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; HOMEOSTASIS; HUMANS; IRON; NEOPLASMS; OXIDATION-REDUCTION;

EID: 85047541890     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19051545     Document Type: Review

References (190)

1. Pantopoulos, K.; Porwal, S.K.; Tartakoff, A.; Devireddy, L. Mechanisms of mammalian iron homeostasis. Biochemistry 2012, 51, 5705-5724. [CrossRef] [PubMed]
2. Hentze, M.W.; Muckenthaler, M.U.; Galy, B.; Camaschella, C. Two to tango: Regulation of mammalian iron metabolism. Cell 2010, 142, 24-38. [CrossRef] [PubMed]
3. Andrews, N.C. Disorders of iron metabolism. N. Engl. J. Med. 1999, 341, 1986-1995. [CrossRef] [PubMed]
4. Wang, J.; Pantopoulos, K. Regulation of cellular iron metabolism. Biochem. J. 2011, 434, 365-381. [CrossRef] [PubMed]
5. Torti, S.V.; Torti, F.M. Iron and cancer: More ore to be mined. Nat. Rev. Cancer 2013, 13, 342-355. [CrossRef] [PubMed]
6. Bystrom, L.M.; Rivella, S. Cancer cells with irons in the fire. Free Radic. Biol. Med. 2015, 79, 337-342. [CrossRef] [PubMed]
7. Ponka, P.; Beaumont, C.; Richardson, D.R. Function and regulation of transferrin and ferritin. Semin. Hematol. 1998, 35, 35-54. [PubMed]
8. Gkouvatsos, K.; Papanikolaou, G.; Pantopoulos, K. Regulation of iron transport and the role of transferrin. Biochim. Biophys. Acta 2012, 1820, 188-202. [CrossRef] [PubMed]
9. Aisen, P. Transferrin receptor 1. Int. J. Biochem. Cell Biol. 2004, 36, 2137-2143. [CrossRef] [PubMed]
10. Ohgami, R.S.; Campagna, D.R.; Greer, E.L.; Antiochos, B.; McDonald, A.; Chen, J.; Sharp, J.J.; Fujiwara, Y.; Barker, J.E.; Fleming, M.D. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet. 2005, 37, 1264-1269. [CrossRef] [PubMed]
11. Gunshin, H.; Mackenzie, B.; Berger, U.V.; Gunshin, Y.; Romero, M.F.; Boron, W.F.; Nussberger, S.; Gollan, J.L.; Hediger, M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997, 388, 482-488. [CrossRef] [PubMed]
12. Chen, C.; Garcia-Santos, D.; Ishikawa, Y.; Seguin, A.; Li, L.; Fegan, K.H.; Hildick-Smith, G.J.; Shah, D.I.; Cooney, J.D.; Chen, W.; et al. Snx3 regulates recycling of the transferrin receptor and iron assimilation. Cell Metab. 2013, 17, 343-352. [CrossRef] [PubMed]
13. Kawabata, H.; Yang, R.; Hirama, T.; Vuong, P.T.; Kawano, S.; Gombart, A.F.; Koeffler, H.P. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J. Biol. Chem. 1999, 274, 20826-20832. [CrossRef] [PubMed]
14. Kawabata, H. Regulation of expression of murine transferrin receptor 2. Blood 2001, 98, 1949-1954. [CrossRef] [PubMed]
15. West, A.P., Jr.; Bennett, M.J.; Sellers, V.M.; Andrews, N.C.; Enns, C.A.; Bjorkman, P.J. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein hfe. J. Biol. Chem. 2000, 275, 38135-38138. [CrossRef] [PubMed]
16. Nai, A.; Lidonnici, M.R.; Rausa, M.; Mandelli, G.; Pagani, A.; Silvestri, L.; Ferrari, G.; Camaschella, C. The second transferrin receptor regulates red blood cell production in mice. Blood 2015, 125, 1170-1179. [CrossRef] [PubMed]
17. Kawabata, H.; Fleming, R.E.; Gui, D.; Moon, S.Y.; Saitoh, T.; O’Kelly, J.; Umehara, Y.; Wano, Y.; Said, J.W.; Koeffler, H.P. Expression of hepcidin is down-regulated in tfr2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2005, 105, 376-381. [CrossRef] [PubMed]
18. Brissot, P.; Ropert, M.; Le Lan, C.; Loreal, O. Non-transferrin bound iron: A key role in iron overload and iron toxicity. Biochim. Biophys. Acta 2012, 1820, 403-410. [CrossRef] [PubMed]
19. McKie, A.T. The role of dcytb in iron metabolism: An update. Biochem. Soc. Trans. 2008, 36, 1239-1241. [CrossRef] [PubMed]
20. Shindo, M.; Torimoto, Y.; Saito, H.; Motomura, W.; Ikuta, K.; Sato, K.; Fujimoto, Y.; Kohgo, Y. Functional role of dmt1 in transferrin-independent iron uptake by human hepatocyte and hepatocellular carcinoma cell, hlf. Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 2006, 35, 152-162. [CrossRef] [PubMed]
21. Liuzzi, J.P.; Aydemir, F.; Nam, H.; Knutson, M.D.; Cousins, R.J. Zip14 (slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc. Natl. Acad. Sci. USA 2006, 103, 13612-13617. [CrossRef] [PubMed]
22. Wang, C.Y.; Jenkitkasemwong, S.; Duarte, S.; Sparkman, B.K.; Shawki, A.; Mackenzie, B.; Knutson, M.D. Zip8 is an iron and zinc transporter whose cell-surface expression is up-regulated by cellular iron loading. J. Biol. Chem. 2012, 287, 34032-34043. [CrossRef] [PubMed]
23. Chen, T.T.; Li, L.; Chung, D.H.; Allen, C.D.; Torti, S.V.; Torti, F.M.; Cyster, J.G.; Chen, C.Y.; Brodsky, F.M.; Niemi, E.C.; et al. Tim-2 is expressed on b cells and in liver and kidney and is a receptor for h-ferritin endocytosis. J. Exp. Med. 2005, 202, 955-965. [CrossRef] [PubMed]
24. Todorich, B.; Zhang, X.; Slagle-Webb, B.; Seaman, W.E.; Connor, J.R. Tim-2 is the receptor for h-ferritin on oligodendrocytes. J. Neurochem. 2008, 107, 1495-1505. [CrossRef] [PubMed]
25. Li, L.; Fang, C.J.; Ryan, J.C.; Niemi, E.C.; Lebron, J.A.; Bjorkman, P.J.; Arase, H.; Torti, F.M.; Torti, S.V.; Nakamura, M.C.; et al. Binding and uptake of h-ferritin are mediated by human transferrin receptor-1. Proc. Natl. Acad. Sci. USA 2010, 107, 3505-3510. [CrossRef] [PubMed]
26. Li, J.Y.; Paragas, N.; Ned, R.M.; Qiu, A.; Viltard, M.; Leete, T.; Drexler, I.R.; Chen, X.; Sanna-Cherchi, S.; Mohammed, F.; et al. Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev. Cell 2009, 16, 35-46. [CrossRef] [PubMed]
27. Rajagopal, A.; Rao, A.U.; Amigo, J.; Tian, M.; Upadhyay, S.K.; Hall, C.; Uhm, S.; Mathew, M.K.; Fleming, M.D.; Paw, B.H.; et al. Haem homeostasis is regulated by the conserved and concerted functions of hrg-1 proteins. Nature 2008, 453, 1127-1131. [CrossRef] [PubMed]
28. Duffy, S.P.; Shing, J.; Saraon, P.; Berger, L.C.; Eiden, M.V.; Wilde, A.; Tailor, C.S. The fowler syndrome-associated protein flvcr2 is an importer of heme. Mol. Cell. Biol. 2010, 30, 5318-5324. [CrossRef] [PubMed]
29. Kristiansen, M.; Graversen, J.H.; Jacobsen, C.; Sonne, O.; Hoffman, H.J.; Law, S.K.; Moestrup, S.K. Identification of the haemoglobin scavenger receptor. Nature 2001, 409, 198-201. [CrossRef] [PubMed]
30. Hvidberg, V.; Maniecki, M.B.; Jacobsen, C.; Hojrup, P.; Moller, H.J.; Moestrup, S.K. Identification of the receptor scavenging hemopexin-heme complexes. Blood 2005, 106, 2572-2579. [CrossRef] [PubMed]
31. Poss, K.D.; Tonegawa, S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc. Natl. Acad. Sci. USA 1997, 94, 10919-10924. [CrossRef] [PubMed]
32. Nandal, A.; Ruiz, J.C.; Subramanian, P.; Ghimire-Rijal, S.; Sinnamon, R.A.; Stemmler, T.L.; Bruick, R.K.; Philpott, C.C. Activation of the hif prolyl hydroxylase by the iron chaperones pcbp1 and pcbp2. Cell Metab. 2011, 14, 647-657. [CrossRef] [PubMed]
33. Frey, A.G.; Nandal, A.; Park, J.H.; Smith, P.M.; Yabe, T.; Ryu, M.S.; Ghosh, M.C.; Lee, J.; Rouault, T.A.; Park, M.H.; et al. Iron chaperones pcbp1 and pcbp2 mediate the metallation of the dinuclear iron enzyme deoxyhypusine hydroxylase. Proc. Natl. Acad. Sci. USA 2014, 111, 8031-8036. [CrossRef] [PubMed]
34. Nordlund, P.; Reichard, P. Ribonucleotide reductases. Annu. Rev. Biochem. 2006, 75, 681-706. [CrossRef] [PubMed]
35. Kurz, T.; Eaton, J.W.; Brunk, U.T. The role of lysosomes in iron metabolism and recycling. Int. J. Biochem. Cell Biol. 2011, 43, 1686-1697. [CrossRef] [PubMed]
36. Shvartsman, M.; Ioav Cabantchik, Z. Intracellular iron trafficking: Role of cytosolic ligands. Biometals 2012, 25, 711-723. [CrossRef] [PubMed]
37. Hamdi, A.; Roshan, T.M.; Kahawita, T.M.; Mason, A.B.; Sheftel, A.D.; Ponka, P. Erythroid cell mitochondria receive endosomal iron by a “kiss-and-run” mechanism. Biochim. Biophys. Acta 2016, 1863, 2859-2867. [CrossRef] [PubMed]
38. Shaw, G.C.; Cope, J.J.; Li, L.; Corson, K.; Hersey, C.; Ackermann, G.E.; Gwynn, B.; Lambert, A.J.; Wingert, R.A.; Traver, D.; et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006, 440, 96-100. [CrossRef] [PubMed]
39. Paradkar, P.N.; Zumbrennen, K.B.; Paw, B.H.; Ward, D.M.; Kaplan, J. Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol. Cell. Biol. 2009, 29, 1007-1016. [CrossRef] [PubMed]
40. Lane, D.J.; Merlot, A.M.; Huang, M.L.; Bae, D.H.; Jansson, P.J.; Sahni, S.; Kalinowski, D.S.; Richardson, D.R. Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease. Biochim. Biophys. Acta 2015, 1853, 1130-1144. [CrossRef] [PubMed]
41. Braymer, J.J.; Lill, R. Iron-sulfur cluster biogenesis and trafficking in mitochondria. J. Biol. Chem. 2017, 292, 12754-12763. [CrossRef] [PubMed]
42. Chiabrando, D.; Vinchi, F.; Fiorito, V.; Mercurio, S.; Tolosano, E. Heme in pathophysiology: A matter of scavenging, metabolism and trafficking across cell membranes. Front. Pharmacol. 2014, 5, 61. [CrossRef] [PubMed]
43. Chiabrando, D.; Marro, S.; Mercurio, S.; Giorgi, C.; Petrillo, S.; Vinchi, F.; Fiorito, V.; Fagoonee, S.; Camporeale, A.; Turco, E.; et al. The mitochondrial heme exporter flvcr1b mediates erythroid differentiation. J. Clin. Investig. 2012, 122, 4569-4579. [CrossRef] [PubMed]
44. Vinchi, F.; Ingoglia, G.; Chiabrando, D.; Mercurio, S.; Turco, E.; Silengo, L.; Altruda, F.; Tolosano, E. Heme exporter flvcr1a regulates heme synthesis and degradation and controls activity of cytochromes p450. Gastroenterology 2014, 146, 1325-1338. [CrossRef] [PubMed]
45. Levi, S.; Corsi, B.; Bosisio, M.; Invernizzi, R.; Volz, A.; Sanford, D.; Arosio, P.; Drysdale, J. A human mitochondrial ferritin encoded by an intronless gene. J. Biol. Chem. 2001, 276, 24437-24440. [CrossRef] [PubMed]
46. Arosio, P.; Levi, S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim. Biophys. Acta 2010, 1800, 783-792. [CrossRef] [PubMed]
47. Shi, H.; Bencze, K.Z.; Stemmler, T.L.; Philpott, C.C. A cytosolic iron chaperone that delivers iron to ferritin. Science 2008, 320, 1207-1210. [CrossRef] [PubMed]
48. Leidgens, S.; Bullough, K.Z.; Shi, H.; Li, F.; Shakoury-Elizeh, M.; Yabe, T.; Subramanian, P.; Hsu, E.; Natarajan, N.; Nandal, A.; et al. Each member of the poly-r(c)-binding protein 1 (PCBP) family exhibits iron chaperone activity toward ferritin. J. Biol. Chem. 2013, 288, 17791-17802. [CrossRef] [PubMed]
49. Asano, T.; Komatsu, M.; Yamaguchi-Iwai, Y.; Ishikawa, F.; Mizushima, N.; Iwai, K. Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. Mol. Cell. Biol. 2011, 31, 2040-2052. [CrossRef] [PubMed]
50. Mancias, J.D.; Pontano Vaites, L.; Nissim, S.; Biancur, D.E.; Kim, A.J.; Wang, X.; Liu, Y.; Goessling, W.; Kimmelman, A.C.; Harper, J.W. Ferritinophagy via ncoa4 is required for erythropoiesis and is regulated by iron dependent herc2-mediated proteolysis. eLife 2015, 4. [CrossRef] [PubMed]
51. Mancias, J.D.; Wang, X.; Gygi, S.P.; Harper, J.W.; Kimmelman, A.C. Quantitative proteomics identifies ncoa4 as the cargo receptor mediating ferritinophagy. Nature 2014, 509, 105-109. [CrossRef] [PubMed]
52. Dowdle, W.E.; Nyfeler, B.; Nagel, J.; Elling, R.A.; Liu, S.; Triantafellow, E.; Menon, S.; Wang, Z.; Honda, A.; Pardee, G.; et al. Selective vps34 inhibitor blocks autophagy and uncovers a role for ncoa4 in ferritin degradation and iron homeostasis in vivo. Nat. Cell Biol. 2014, 16, 1069-1079. [CrossRef] [PubMed]
53. Philpott, C.C.; Ryu, M.S.; Frey, A.; Patel, S. Cytosolic iron chaperones: Proteins delivering iron cofactors in the cytosol of mammalian cells. J. Biol. Chem. 2017, 292, 12764-12771. [CrossRef] [PubMed]
54. Bellelli, R.; Federico, G.; Matte, A.; Colecchia, D.; Iolascon, A.; Chiariello, M.; Santoro, M.; De Franceschi, L.; Carlomagno, F. Ncoa4 deficiency impairs systemic iron homeostasis. Cell Rep. 2016, 14, 411-421. [CrossRef] [PubMed]
55. Donovan, A.; Lima, C.A.; Pinkus, J.L.; Pinkus, G.S.; Zon, L.I.; Robine, S.; Andrews, N.C. The iron exporter ferroportin/slc40a1 is essential for iron homeostasis. Cell Metab. 2005, 1, 191-200. [CrossRef] [PubMed]
56. Yanatori, I.; Yasui, Y.; Tabuchi, M.; Kishi, F. Chaperone protein involved in transmembrane transport of iron. Biochem. J. 2014, 462, 25-37. [CrossRef] [PubMed]
57. Yanatori, I.; Richardson, D.R.; Imada, K.; Kishi, F. Iron export through the transporter ferroportin 1 is modulated by the iron chaperone pcbp2. J. Biol. Chem. 2016, 291, 17303-17318. [CrossRef] [PubMed]
58. Vashchenko, G.; MacGillivray, R.T. Multi-copper oxidases and human iron metabolism. Nutrients 2013, 5, 2289-2313. [CrossRef] [PubMed]
59. Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090-2093. [CrossRef] [PubMed]
60. Piccinelli, P.; Samuelsson, T. Evolution of the iron-responsive element. RNA 2007, 13, 952-966. [CrossRef] [PubMed]
61. Muckenthaler, M.U.; Galy, B.; Hentze, M.W. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (ire/irp) regulatory network. Annu. Rev. Nutr. 2008, 28, 197-213. [CrossRef] [PubMed]
62. Luscieti, S.; Galy, B.; Gutierrez, L.; Reinke, M.; Couso, J.; Shvartsman, M.; Di Pascale, A.; Witke, W.; Hentze, M.W.; Pilo Boyl, P.; et al. The actin binding protein profilin 2 is a novel regulator of iron homeostasis. Blood 2017, 130, 1934-1945. [CrossRef] [PubMed]
63. Recalcati, S.; Minotti, G.; Cairo, G. Iron regulatory proteins: From molecular mechanisms to drug development. Antioxid. Redox Signal. 2010, 13, 1593-1616. [CrossRef] [PubMed]
64. Meyron-Holtz, E.G.; Ghosh, M.C.; Rouault, T.A. Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science 2004, 306, 2087-2090. [CrossRef] [PubMed]
65. Zimmer, M.; Ebert, B.L.; Neil, C.; Brenner, K.; Papaioannou, I.; Melas, A.; Tolliday, N.; Lamb, J.; Pantopoulos, K.; Golub, T.; et al. Small-molecule inhibitors of hif-2a translation link its 5’utr iron-responsive element to oxygen sensing. Mol. Cell 2008, 32, 838-848. [CrossRef] [PubMed]
66. Cairo, G.; Castrusini, E.; Minotti, G.; Bernelli-Zazzera, A. Superoxide and hydrogen peroxide-dependent inhibition of iron regulatory protein activity: A protective stratagem against oxidative injury. FASEB J. 1996, 10, 1326-1335. [CrossRef] [PubMed]
67. Orino, K.; Lehman, L.; Tsuji, Y.; Ayaki, H.; Torti, S.V.; Torti, F.M. Ferritin and the response to oxidative stress. Biochem. J. 2001, 357, 241-247. [CrossRef] [PubMed]
68. Mattace Raso, G.; Irace, C.; Esposito, E.; Maffettone, C.; Iacono, A.; Di Pascale, A.; Santamaria, R.; Colonna, A.; Meli, R. Ovariectomy and estrogen treatment modulate iron metabolism in rat adipose tissue. Biochem. Pharmacol. 2009, 78, 1001-1007. [CrossRef] [PubMed]
69. Gu, J.M.; Lim, S.O.; Oh, S.J.; Yoon, S.M.; Seong, J.K.; Jung, G. Hbx modulates iron regulatory protein 1-mediated iron metabolism via reactive oxygen species. Virus Res. 2008, 133, 167-177. [CrossRef] [PubMed]
70. Maffettone, C.; De Martino, L.; Irace, C.; Santamaria, R.; Pagnini, U.; Iovane, G.; Colonna, A. Expression of iron-related proteins during infection by bovine herpes virus type-1. J. Cell. Biochem. 2008, 104, 213-223. [CrossRef] [PubMed]
71. Stehling, O.; Mascarenhas, J.; Vashisht, A.A.; Sheftel, A.D.; Niggemeyer, B.; Rosser, R.; Pierik, A.J.; Wohlschlegel, J.A.; Lill, R. Human cia2a-fam96a and cia2b-fam96b integrate iron homeostasis and maturation of different subsets of cytosolic-nuclear iron-sulfur proteins. Cell Metab. 2013, 18, 187-198. [CrossRef] [PubMed]
72. Thompson, J.W.; Salahudeen, A.A.; Chollangi, S.; Ruiz, J.C.; Brautigam, C.A.; Makris, T.M.; Lipscomb, J.D.; Tomchick, D.R.; Bruick, R.K. Structural and molecular characterization of iron-sensing hemerythrin-like domain within f-box and leucine-rich repeat protein 5 (fbxl5). J. Biol. Chem. 2012, 287, 7357-7365. [CrossRef] [PubMed]
73. Walden, W.E.; Selezneva, A.I.; Dupuy, J.; Volbeda, A.; Fontecilla-Camps, J.C.; Theil, E.C.; Volz, K. Structure of dual function iron regulatory protein 1 complexed with ferritin ire-rna. Science 2006, 314, 1903-1908. [CrossRef] [PubMed]
74. Salahudeen, A.A.; Thompson, J.W.; Ruiz, J.C.; Ma, H.W.; Kinch, L.N.; Li, Q.; Grishin, N.V.; Bruick, R.K. An e3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science 2009, 326, 722-726. [CrossRef] [PubMed]
75. Vashisht, A.A.; Zumbrennen, K.B.; Huang, X.; Powers, D.N.; Durazo, A.; Sun, D.; Bhaskaran, N.; Persson, A.; Uhlen, M.; Sangfelt, O.; et al. Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science 2009, 326, 718-721. [CrossRef] [PubMed]
76. Boult, J.; Roberts, K.; Brookes, M.J.; Hughes, S.; Bury, J.P.; Cross, S.S.; Anderson, G.J.; Spychal, R.; Iqbal, T.; Tselepis, C. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin. Cancer Res. 2008, 14, 379-387. [CrossRef] [PubMed]
77. Marques, O.; Porto, G.; Rema, A.; Faria, F.; Cruz Paula, A.; Gomez-Lazaro, M.; Silva, P.; Martins da Silva, B.; Lopes, C. Local iron homeostasis in the breast ductal carcinoma microenvironment. BMC Cancer 2016, 16, 187. [CrossRef] [PubMed]
78. Jiang, X.P.; Elliott, R.L.; Head, J.F. Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res. 2010, 30, 759-765. [PubMed]
79. Wang, W.; Deng, Z.; Hatcher, H.; Miller, L.D.; Di, X.; Tesfay, L.; Sui, G.; D’Agostino, R.B., Jr.; Torti, F.M.; Torti, S.V. Irp2 regulates breast tumor growth. Cancer Res. 2014, 74, 497-507. [CrossRef] [PubMed]
80. Radulescu, S.; Brookes, M.J.; Salgueiro, P.; Ridgway, R.A.; McGhee, E.; Anderson, K.; Ford, S.J.; Stones, D.H.; Iqbal, T.H.; Tselepis, C.; et al. Luminal iron levels govern intestinal tumorigenesis after apc loss in vivo. Cell Rep. 2012, 2, 270-282. [CrossRef] [PubMed]
81. Brookes, M.J. Modulation of iron transport proteins in human colorectal carcinogenesis. Gut 2006, 55, 1449-1460. [CrossRef] [PubMed]
82. Schonberg, D.L.; Miller, T.E.; Wu, Q.; Flavahan, W.A.; Das, N.K.; Hale, J.S.; Hubert, C.G.; Mack, S.C.; Jarrar, A.M.; Karl, R.T.; et al. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 2015, 28, 441-455. [CrossRef] [PubMed]
83. Chirasani, S.R.; Markovic, D.S.; Synowitz, M.; Eichler, S.A.; Wisniewski, P.; Kaminska, B.; Otto, A.; Wanker, E.; Schafer, M.; Chiarugi, P.; et al. Transferrin-receptor-mediated iron accumulation controls proliferation and glutamate release in glioma cells. J. Mol. Med. 2009, 87, 153-167. [CrossRef] [PubMed]
84. Basuli, D.; Tesfay, L.; Deng, Z.; Paul, B.; Yamamoto, Y.; Ning, G.; Xian, W.; McKeon, F.; Lynch, M.; Crum, C.P.; et al. Iron addiction: A novel therapeutic target in ovarian cancer. Oncogene 2017, 36, 4089-4099. [CrossRef] [PubMed]
85. Bogdan, A.R.; Miyazawa, M.; Hashimoto, K.; Tsuji, Y. Regulators of iron homeostasis: New players in metabolism, cell death, and disease. Trends Biochem. Sci. 2016, 41, 274-286. [CrossRef] [PubMed]
86. Calzolari, A.; Oliviero, I.; Deaglio, S.; Mariani, G.; Biffoni, M.; Sposi, N.M.; Malavasi, F.; Peschle, C.; Testa, U. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol. Dis. 2007, 39, 82-91. [CrossRef] [PubMed]
87. Calzolari, A.; Larocca, L.M.; Deaglio, S.; Finisguerra, V.; Boe, A.; Raggi, C.; Ricci-Vitani, L.; Pierconti, F.; Malavasi, F.; De Maria, R.; et al. Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl. Oncol. 2010, 3, 123-134. [CrossRef] [PubMed]
88. Xue, X.; Ramakrishnan, S.K.; Weisz, K.; Triner, D.; Xie, L.; Attili, D.; Pant, A.; Gyorffy, B.; Zhan, M.; Carter-Su, C.; et al. Iron uptake via dmt1 integrates cell cycle with jak-stat3 signaling to promote colorectal tumorigenesis. Cell Metab. 2016, 24, 447-461. [CrossRef] [PubMed]
89. Yang, J.; Bielenberg, D.R.; Rodig, S.J.; Doiron, R.; Clifton, M.C.; Kung, A.L.; Strong, R.K.; Zurakowski, D.; Moses, M.A. Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. USA 2009, 106, 3913-3918. [CrossRef] [PubMed]
90. Chung, I.H.; Wu, T.I.; Liao, C.J.; Hu, J.Y.; Lin, Y.H.; Tai, P.J.; Lai, C.H.; Lin, K.H. Overexpression of lipocalin 2 in human cervical cancer enhances tumor invasion. Oncotarget 2016, 7, 11113-11126. [CrossRef] [PubMed]
91. Chiang, K.C.; Yeh, T.S.; Wu, R.C.; Pang, J.S.; Cheng, C.T.; Wang, S.Y.; Juang, H.H.; Yeh, C.N. Lipocalin 2 (lcn2) is a promising target for cholangiocarcinoma treatment and bile lcn2 level is a potential cholangiocarcinoma diagnostic marker. Sci. Rep. 2016, 6, 36138. [CrossRef] [PubMed]
92. Leung, L.; Radulovich, N.; Zhu, C.Q.; Organ, S.; Bandarchi, B.; Pintilie, M.; To, C.; Panchal, D.; Tsao, M.S. Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS ONE 2012, 7, e46677. [CrossRef] [PubMed]
93. Shpyleva, S.I.; Tryndyak, V.P.; Kovalchuk, O.; Starlard-Davenport, A.; Chekhun, V.F.; Beland, F.A.; Pogribny, I.P. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res. Treat. 2011, 126, 63-71. [CrossRef] [PubMed]
94. Horniblow, R.D.; Bedford, M.; Hollingworth, R.; Evans, S.; Sutton, E.; Lal, N.; Beggs, A.; Iqbal, T.H.; Tselepis, C. Braf mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis. Cancer Sci. 2017, 108, 1135-1143. [CrossRef] [PubMed]
95. Khiroya, H.; Moore, J.S.; Ahmad, N.; Kay, J.; Woolnough, K.; Langman, G.; Ismail, I.; Naidu, B.; Tselepis, C.; Turner, A.M. Irp2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer. Eur. Respir. J. 2017, 49, 1600711. [CrossRef] [PubMed]
96. Zhang, S.; Chen, Y.; Guo, W.; Yuan, L.; Zhang, D.; Xu, Y.; Nemeth, E.; Ganz, T.; Liu, S. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell. Signal. 2014, 26, 2539-2550. [CrossRef] [PubMed]
97. Pinnix, Z.K.; Miller, L.D.; Wang, W.; D’Agostino, R., Jr.; Kute, T.; Willingham, M.C.; Hatcher, H.; Tesfay, L.; Sui, G.; Di, X.; et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med. 2010, 2, 43ra56. [CrossRef] [PubMed]
98. Babu, K.R.; Muckenthaler, M.U. Mir-20a regulates expression of the iron exporter ferroportin in lung cancer. J. Mol. Med. (Berl.) 2016, 94, 347-359. [CrossRef] [PubMed]
99. Tesfay, L.; Clausen, K.A.; Kim, J.W.; Hegde, P.; Wang, X.; Miller, L.D.; Deng, Z.; Blanchette, N.; Arvedson, T.; Miranti, C.K.; et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 2015, 75, 2254-2263. [CrossRef] [PubMed]
100. Xue, D.; Zhou, C.X.; Shi, Y.B.; Lu, H.; He, X.Z. Decreased expression of ferroportin in prostate cancer. Oncol. Lett. 2015, 10, 913-916. [CrossRef] [PubMed]
101. Chen, Y.; Zhang, Z.; Yang, K.; Du, J.; Xu, Y.; Liu, S. Myeloid zinc-finger 1 (mzf-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress. Oncogene 2015, 34, 3839-3847. [CrossRef] [PubMed]
102. He, L.; Hannon, G.J. Micrornas: Small rnas with a big role in gene regulation. Nat. Rev. Genet. 2004, 5, 522-531. [CrossRef] [PubMed]
103. Davis, M.; Clarke, S. Influence of microrna on the maintenance of human iron metabolism. Nutrients 2013, 5, 2611-2628. [CrossRef] [PubMed]
104. Yoshioka, Y.; Kosaka, N.; Ochiya, T.; Kato, T. Micromanaging iron homeostasis: Hypoxia-inducible micro-rna-210 suppresses iron homeostasis-related proteins. J. Biol. Chem. 2012, 287, 34110-34119. [CrossRef] [PubMed]
105. McCormick, R.I.; Blick, C.; Ragoussis, J.; Schoedel, J.; Mole, D.R.; Young, A.C.; Selby, P.J.; Banks, R.E.; Harris, A.L. Mir-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates iscu and correlates with good prognosis. Br. J. Cancer 2013, 108, 1133-1142. [CrossRef] [PubMed]
106. Kindrat, I.; Tryndyak, V.; de Conti, A.; Shpyleva, S.; Mudalige, T.K.; Kobets, T.; Erstenyuk, A.M.; Beland, F.A.; Pogribny, I.P. Microrna-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis. Oncotarget 2016, 7, 1276-1287. [CrossRef] [PubMed]
107. Andolfo, I.; De Falco, L.; Asci, R.; Russo, R.; Colucci, S.; Gorrese, M.; Zollo, M.; Iolascon, A. Regulation of divalent metal transporter 1 (dmt1) non-ire isoform by the microrna let-7d in erythroid cells. Haematologica 2010, 95, 1244-1252. [CrossRef] [PubMed]
108. Sangokoya, C.; Doss, J.F.; Chi, J.T. Iron-responsive mir-485-3p regulates cellular iron homeostasis by targeting ferroportin. PLoS Genet. 2013, 9, e1003408. [CrossRef] [PubMed]
109. Daniels, T.R.; Bernabeu, E.; Rodriguez, J.A.; Patel, S.; Kozman, M.; Chiappetta, D.A.; Holler, E.; Ljubimova, J.Y.; Helguera, G.; Penichet, M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 2012, 1820, 291-317. [CrossRef] [PubMed]
110. O’Donnell, K.A.; Yu, D.; Zeller, K.I.; Kim, J.W.; Racke, F.; Thomas-Tikhonenko, A.; Dang, C.V. Activation of transferrin receptor 1 by c-myc enhances cellular proliferation and tumorigenesis. Mol. Cell. Biol. 2006, 26, 2373-2386. [CrossRef] [PubMed]
111. Jeong, S.M.; Hwang, S.; Seong, R.H. Transferrin receptor regulates pancreatic cancer growth by modulating mitochondrial respiration and ros generation. Biochem. Biophys. Res. Commun. 2016, 471, 373-379. [CrossRef] [PubMed]
112. Wang, B.; Zhang, J.; Song, F.; Tian, M.; Shi, B.; Jiang, H.; Xu, W.; Wang, H.; Zhou, M.; Pan, X.; et al. Egfr regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1. Cancer Lett. 2016, 381, 331-340. [CrossRef] [PubMed]
113. Calzolari, A.; Finisguerra, V.; Oliviero, I.; Deaglio, S.; Mariani, G.; Malavasi, F.; Testa, U. Regulation of transferrin receptor 2 in human cancer cell lines. Blood Cells Mol. Dis. 2009, 42, 5-13. [CrossRef] [PubMed]
114. Lemler, D.J.; Lynch, M.L.; Tesfay, L.; Deng, Z.; Paul, B.T.; Wang, X.; Hegde, P.; Manz, D.H.; Torti, S.V.; Torti, F.M. Dcytb is a predictor of outcome in breast cancer that functions via iron-independent mechanisms. Breast Cancer Res. BCR 2017, 19, 25. [CrossRef] [PubMed]
115. You, K.; Su, F.; Liu, L.; Lv, X.; Zhang, J.; Zhang, Y.; Liu, B. Scara5 plays a critical role in the progression and metastasis of breast cancer by inactivating the erk1/2, stat3, and akt signaling pathways. Mol. Cell. Biochem. 2017, 435, 47-58. [CrossRef] [PubMed]
116. Chau, L.Y. Heme oxygenase-1: Emerging target of cancer therapy. J. Biomed. Sci. 2015, 22, 22. [CrossRef] [PubMed]
117. Gomes, I.M.; Maia, C.J.; Santos, C.R. Steap proteins: From structure to applications in cancer therapy. Mol. Cancer Res. MCR 2012, 10, 573-587. [CrossRef] [PubMed]
118. Isobe, T.; Baba, E.; Arita, S.; Komoda, M.; Tamura, S.; Shirakawa, T.; Ariyama, H.; Takaishi, S.; Kusaba, H.; Ueki, T.; et al. Human steap3 maintains tumor growth under hypoferric condition. Exp. Cell Res. 2011, 317, 2582-2591. [CrossRef] [PubMed]
119. Jung, M.; Mertens, C.; Bauer, R.; Rehwald, C.; Brune, B. Lipocalin-2 and iron trafficking in the tumor microenvironment. Pharmacol. Res. 2017, 120, 146-156. [CrossRef] [PubMed]
120. Tung, M.C.; Hsieh, S.C.; Yang, S.F.; Cheng, C.W.; Tsai, R.T.; Wang, S.C.; Huang, M.H.; Hsieh, Y.H. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells. Prostate 2013, 73, 1281-1290. [CrossRef] [PubMed]
121. Yang, J.; McNeish, B.; Butterfield, C.; Moses, M.A. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2013, 27, 45-50. [CrossRef] [PubMed]
122. Manz, D.H.; Blanchette, N.L.; Paul, B.T.; Torti, F.M.; Torti, S.V. Iron and cancer: Recent insights. Ann. N. Y. Acad. Sci. 2016, 1368, 149-161. [CrossRef] [PubMed]
123. Kwak, E.L.; Larochelle, D.A.; Beaumont, C.; Torti, S.V.; Torti, F.M. Role for nf-kappa b in the regulation of ferritin h by tumor necrosis factor-α. J. Biol. Chem. 1995, 270, 15285-15293. [CrossRef] [PubMed]
124. Rogers, J.T.; Bridges, K.R.; Durmowicz, G.P.; Glass, J.; Auron, P.E.; Munro, H.N. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J. Biol. Chem. 1990, 265, 14572-14578. [PubMed]
125. Alkhateeb, A.A.; Connor, J.R. The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis. Biochim. Biophys. Acta 2013, 1836, 245-254. [CrossRef] [PubMed]
126. Wu, K.J.; Polack, A.; Dalla-Favera, R. Coordinated regulation of iron-controlling genes, h-ferritin and irp2, by c-myc. Science 1999, 283, 676-679. [CrossRef] [PubMed]
127. Xue, D.; Zhou, C.; Shi, Y.; Lu, H.; Xu, R.; He, X. Nuclear transcription factor nrf2 suppresses prostate cancer cells growth and migration through upregulating ferroportin. Oncotarget 2016, 7, 78804-78812. [CrossRef] [PubMed]
128. Yang, X.; Park, S.H.; Chang, H.C.; Shapiro, J.S.; Vassilopoulos, A.; Sawicki, K.T.; Chen, C.; Shang, M.; Burridge, P.W.; Epting, C.L.; et al. Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor nrf2. J. Clin. Investig. 2017, 127, 1505-1516. [CrossRef] [PubMed]
129. Wang, Y.F.; Zhang, J.; Su, Y.; Shen, Y.Y.; Jiang, D.X.; Hou, Y.Y.; Geng, M.Y.; Ding, J.; Chen, Y. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat. Commun. 2017, 8, 274. [CrossRef] [PubMed]
130. Cheng, C.M.; Wang, D.; Cao, X.; Luo, Q.Q.; Lu, Y.P.; Zhu, L. Iron regulatory protein 1 suppresses hypoxia-induced iron uptake proteins expression and decreases iron levels in hepg2 cells. J. Cell. Biochem. 2015, 116, 1919-1931. [CrossRef] [PubMed]
131. Jeong, S.M.; Lee, J.; Finley, L.W.; Schmidt, P.J.; Fleming, M.D.; Haigis, M.C. Sirt3 regulates cellular iron metabolism and cancer growth by repressing iron regulatory protein 1. Oncogene 2015, 34, 2115-2124. [CrossRef] [PubMed]
132. Neufeld, E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: New data, new questions. Blood 2006, 107, 3436-3441. [CrossRef] [PubMed]
133. Yu, Y.; Kovacevic, Z.; Richardson, D.R. Tuning cell cycle regulation with an iron key. Cell Cycle 2007, 6, 1982-1994. [CrossRef] [PubMed]
134. Estrov, Z.; Tawa, A.; Wang, X.H.; Dube, I.D.; Sulh, H.; Cohen, A.; Gelfand, E.W.; Freedman, M.H. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987, 69, 757-761. [PubMed]
135. Becton, D.L.; Bryles, P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res. 1988, 48, 7189-7192. [PubMed]
136. Keeler, B.D.; Brookes, M.J. Iron chelation: A potential therapeutic strategy in oesophageal cancer. Br. J. Pharmacol. 2013, 168, 1313-1315. [CrossRef] [PubMed]
137. Yamasaki, T.; Terai, S.; Sakaida, I. Deferoxamine for advanced hepatocellular carcinoma. N. Engl. J. Med. 2011, 365, 576-578. [CrossRef] [PubMed]
138. Hershko, C.; Konijn, A.M.; Nick, H.P.; Link, G. Icl670a, a powerful new synthetic oral iron chelator: Evaluation in hypertransfused rats and in cultured iron-loaded rat heart cells. Blood 2000, 96, 225a.
139. Choi, J.H.; Kim, J.S.; Won, Y.W.; Uhm, J.; Park, B.B.; Lee, Y.Y. The potential of deferasirox as a novel therapeutic modality in gastric cancer. World J. Surg. Oncol. 2016, 14, 77. [CrossRef] [PubMed]
140. Lui, G.Y.; Obeidy, P.; Ford, S.J.; Tselepis, C.; Sharp, D.M.; Jansson, P.J.; Kalinowski, D.S.; Kovacevic, Z.; Lovejoy, D.B.; Richardson, D.R. The iron chelator, deferasirox, as a novel strategy for cancer treatment: Oral activity against human lung tumor xenografts and molecular mechanism of action. Mol. Pharmacol. 2013, 83, 179-190. [CrossRef] [PubMed]
141. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA 2006, 103, 14901-14906. [CrossRef] [PubMed]
142. Noulsri, E.; Richardson, D.R.; Lerdwana, S.; Fucharoen, S.; Yamagishi, T.; Kalinowski, D.S.; Pattanapanyasat, K. Antitumor activity and mechanism of action of the iron chelator, dp44mt, against leukemic cells. Am. J. Hematol. 2009, 84, 170-176. [CrossRef] [PubMed]
143. Lee, J.C.; Chiang, K.C.; Feng, T.H.; Chen, Y.J.; Chuang, S.T.; Tsui, K.H.; Chung, L.C.; Juang, H.H. The iron chelator, dp44mt, effectively inhibits human oral squamous cell carcinoma cell growth in vitro and in vivo. Int. J. Mol. Sci. 2016, 17, 1435. [CrossRef] [PubMed]
144. Jansson, P.J.; Hawkins, C.L.; Lovejoy, D.B.; Richardson, D.R. The iron complex of dp44mt is redox-active and induces hydroxyl radical formation: An epr study. J. Inorg. Biochem. 2010, 104, 1224-1228. [CrossRef] [PubMed]
145. Richardson, D.R.; Sharpe, P.C.; Lovejoy, D.B.; Senaratne, D.; Kalinowski, D.S.; Islam, M.; Bernhardt, P.V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006, 49, 6510-6521. [CrossRef] [PubMed]
146. Dusek, P.; Schneider, S.A.; Aaseth, J. Iron chelation in the treatment of neurodegenerative diseases. J. Trace Elem. Med. Biol. 2016, 38, 81-92. [CrossRef] [PubMed]
147. Merlot, A.M.; Kalinowski, D.S.; Richardson, D.R. Novel chelators for cancer treatment: Where are we now? Antioxid. Redox Signal. 2013, 18, 973-1006. [CrossRef] [PubMed]
148. Raza, M.; Chakraborty, S.; Choudhury, M.; Ghosh, P.C.; Nag, A. Cellular iron homeostasis and therapeutic implications of iron chelators in cancer. Curr. Pharm. Biotechnol. 2014, 15, 1125-1140. [CrossRef] [PubMed]
149. Eid, R.; Arab, N.T.; Greenwood, M.T. Iron mediated toxicity and programmed cell death: A review and a re-examination of existing paradigms. Biochim. Biophys. Acta 2017, 1864, 399-430. [CrossRef] [PubMed]
150. Hait, W.N.; Hambley, T.W. Targeted cancer therapeutics. Cancer Res. 2009, 69, 1263-1267. [CrossRef] [PubMed]
151. Lee, H.J.; Engelhardt, B.; Lesley, J.; Bickel, U.; Pardridge, W.M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharm. Exp. Ther. 2000, 292, 1048-1052.
152. Xu, L.; Huang, C.C.; Huang, W.; Tang, W.H.; Rait, A.; Yin, Y.Z.; Cruz, I.; Xiang, L.M.; Pirollo, K.F.; Chang, E.H. Systemic tumor-targeted gene delivery by anti-transferrin receptor scfv-immunoliposomes. Mol. Cancer Ther. 2002, 1, 337-346. [PubMed]
153. Oh, S.; Kim, B.J.; Singh, N.P.; Lai, H.; Sasaki, T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett. 2009, 274, 33-39. [CrossRef] [PubMed]
154. Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 2012, 63, 185-198. [CrossRef] [PubMed]
155. Sankhala, K.K.; Mita, A.C.; Adinin, R.; Wood, L.; Beeram, M.; Bullock, S.; Yamagata, N.; Matsuno, K.; Fujisawa, T.; Phan, A. A phase i pharmacokinetic (pk) study of mbp-426, a novel liposome encapsulated oxaliplatin. J. Clin. Oncol. 2009, 27.
156. Van der Meel, R.; Vehmeijer, L.J.; Kok, R.J.; Storm, G.; van Gaal, E.V. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Adv. Drug Deliv. Rev. 2013, 65, 1284-1298. [CrossRef] [PubMed]
157. Guo, P.; Yang, J.; Jia, D.; Moses, M.A.; Auguste, D.T. Icam-1-targeted, lcn2 sirna-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer. Theranostics 2016, 6, 1-13. [CrossRef] [PubMed]
158. Perez-Sayans, M.; Somoza-Martin, J.M.; Barros-Angueira, F.; Rey, J.M.G.; Garcia-Garcia, A. V-atpase inhibitors and implication in cancer treatment. Cancer Treat. Rev. 2009, 35, 707-713. [CrossRef] [PubMed]
159. Schneider, L.S.; von Schwarzenberg, K.; Lehr, T.; Ulrich, M.; Kubisch-Dohmen, R.; Liebl, J.; Trauner, D.; Menche, D.; Vollmar, A.M. Vacuolar-atpase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer. Cancer Res. 2015, 75, 2863-2874. [CrossRef] [PubMed]
160. Zhang, S.; Schneider, L.S.; Vick, B.; Grunert, M.; Jeremias, I.; Menche, D.; Muller, R.; Vollmar, A.M.; Liebl, J. Anti-leukemic effects of the V-ATPase inhibitor Archazolid A. Oncotarget 2015, 6, 43508-43528. [CrossRef] [PubMed]
161. Bhushan, B.; Kumar, S.U.; Matai, I.; Sachdev, A.; Dubey, P.; Gopinath, P. Ferritin nanocages: A novel platform for biomedical applications. J. Biomed. Nanotechnol. 2014, 10, 2950-2976. [CrossRef] [PubMed]
162. Zhang, L.B.; Fischer, W.; Pippel, E.; Hause, G.; Brandsch, M.; Knez, M. Receptor-mediated cellular uptake of nanoparticles: A switchable delivery system. Small 2011, 7, 1538-1541. [CrossRef] [PubMed]
163. Geninatti Crich, S.; Cadenazzi, M.; Lanzardo, S.; Conti, L.; Ruiu, R.; Alberti, D.; Cavallo, F.; Cutrin, J.C.; Aime, S. Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. Nanoscale 2015, 7, 6527-6533. [CrossRef] [PubMed]
164. Chekhun, V.F.; Lukyanova, N.Y.; Burlaka, C.A.; Bezdenezhnykh, N.A.; Shpyleva, S.I.; Tryndyak, V.P.; Beland, F.A.; Pogribny, I.P. Iron metabolism disturbances in the mcf-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int. J. Oncol. 2013, 43, 1481-1486. [CrossRef] [PubMed]
165. Crielaard, B.J.; Lammers, T.; Rivella, S. Targeting iron metabolism in drug discovery and delivery. Nat. Rev. Drug Discov. 2017, 16, 400-423. [CrossRef] [PubMed]
166. Bystrom, L.M.; Guzman, M.L.; Rivella, S. Iron and reactive oxygen species friends or foes of cancer cells. Pdf. Antiox. Redox Signal. 2014, 20, 1917-1924. [CrossRef] [PubMed]
167. Stockwell, B.R.; Friedmann Angeli, J.P.; Bayir, H.; Bush, A.I.; Conrad, M.; Dixon, S.J.; Fulda, S.; Gascon, S.; Hatzios, S.K.; Kagan, V.E.; et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017, 171, 273-285. [CrossRef] [PubMed]
168. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012, 149, 1060-1072. [CrossRef] [PubMed]
169. Yang, W.S.; SriRamaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.; Clemons, P.A.; Shamji, A.F.; Clish, C.B.; et al. Regulation of ferroptotic cancer cell death by gpx4. Cell 2014, 156, 317-331. [CrossRef] [PubMed]
170. Dixon, S.J.; Patel, D.N.; Welsch, M.; Skouta, R.; Lee, E.D.; Hayano, M.; Thomas, A.G.; Gleason, C.E.; Tatonetti, N.P.; Slusher, B.S.; et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 2014, 3, e02523. [CrossRef] [PubMed]
171. Lachaier, E.; Louandre, C.; Godin, C.; Saidak, Z.; Baert, M.; Diouf, M.; Chauffert, B.; Galmiche, A. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014, 34, 6417-6422. [PubMed]
172. Sun, X.; Niu, X.; Chen, R.; He, W.; Chen, D.; Kang, R.; Tang, D. Metallothionein-1g facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 2016, 64, 488-500. [CrossRef] [PubMed]
173. Louandre, C.; Ezzoukhry, Z.; Godin, C.; Barbare, J.C.; Maziere, J.C.; Chauffert, B.; Galmiche, A. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int. J. Cancer 2013, 133, 1732-1742. [CrossRef] [PubMed]
174. Louandre, C.; Marcq, I.; Bouhlal, H.; Lachaier, E.; Godin, C.; Saidak, Z.; Francois, C.; Chatelain, D.; Debuysscher, V.; Barbare, J.C.; et al. The retinoblastoma (rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 2015, 356, 971-977. [CrossRef] [PubMed]
175. Zhang, F.; Gosser, D.K., Jr.; Meshnick, S.R. Hemin-catalyzed decomposition of artemisinin (qinghaosu). Biochem. Pharmacol. 1992, 43, 1805-1809. [CrossRef]
176. Eckstein-Ludwig, U.; Webb, R.J.; Van Goethem, I.D.; East, J.M.; Lee, A.G.; Kimura, M.; O’Neill, P.M.; Bray, P.G.; Ward, S.A.; Krishna, S. Artemisinins target the serca of plasmodium falciparum. Nature 2003, 424, 957-961. [CrossRef] [PubMed]
177. Lai, H.; Sasaki, T.; Singh, N.P. Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. Expert Opin. Ther. Targets 2005, 9, 995-1007. [CrossRef] [PubMed]
178. Wondrak, G.T. Redox-directed cancer therapeutics: Molecular mechanisms and opportunities. Antiox. Redox Signal. 2009, 11, 3013-3069. [CrossRef] [PubMed]
179. Bhaw-Luximon, A.; Jhurry, D. Artemisinin and its derivatives in cancer therapy: Status of progress, mechanism of action, and future perspectives. Cancer Chemother. Pharmacol. 2017, 79, 451-466. [CrossRef] [PubMed]
180. Ooko, E.; Saeed, M.E.; Kadioglu, O.; Sarvi, S.; Colak, M.; Elmasaoudi, K.; Janah, R.; Greten, H.J.; Efferth, T. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomed. Int. J. Phytother. Phytopharmacol. 2015, 22, 1045-1054. [CrossRef] [PubMed]
181. Lin, R.; Zhang, Z.; Chen, L.; Zhou, Y.; Zou, P.; Feng, C.; Wang, L.; Liang, G. Dihydroartemisinin (dha) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells. Cancer Lett. 2016, 381, 165-175. [CrossRef] [PubMed]
182. Greenshields, A.L.; Shepherd, T.G.; Hoskin, D.W. Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate. Mol. Carcinog. 2017, 56, 75-93. [CrossRef] [PubMed]
183. Banhegyi, G.; Braun, L.; Csala, M.; Puskas, F.; Mandl, J. Ascorbate metabolism and its regulation in animals. Free Radic. Biol. Med. 1997, 23, 793-803. [CrossRef]
184. Halliwell, B. Antioxidants in human health and disease. Annu. Rev. Nutr. 1996, 16, 33-50. [CrossRef] [PubMed]
185. Buettner, G.R.; Jurkiewicz, B.A. Catalytic metals, ascorbate and free radicals: Combinations to avoid. Radiat. Res. 1996, 145, 532-541. [CrossRef] [PubMed]
186. Chen, Q.; Espey, M.G.; Krishna, M.C.; Mitchell, J.B.; Corpe, C.P.; Buettner, G.R.; Shacter, E.; Levine, M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad. Sci. USA 2005, 102, 13604-13609. [CrossRef] [PubMed]
187. Hoffer, L.J.; Levine, M.; Assouline, S.; Melnychuk, D.; Padayatty, S.J.; Rosadiuk, K.; Rousseau, C.; Robitaille, L.; Miller, W.H., Jr. Phase i clinical trial of i.V. Ascorbic acid in advanced malignancy. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2008, 19, 1969-1974. [CrossRef] [PubMed]
188. Ma, Y.; Chapman, J.; Levine, M.; Polireddy, K.; Drisko, J.; Chen, Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci. Transl. Med. 2014, 6, 222ra218. [CrossRef] [PubMed]
189. 2 -mediated disruption of fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell 2017, 31, 487-500. [CrossRef] [PubMed]
190. Polireddy, K.; Dong, R.; Reed, G.; Yu, J.; Chen, P.; Williamson, S.; Violet, P.C.; Pessetto, Z.; Godwin, A.K.; Fan, F.; et al. High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: Mechanisms and a phase i/iia study. Sci. Rep. 2017, 7, 17188. [CrossRef] [PubMed]